Evidence-grounded judgment for oncology dealmaking.
Partnering, licensing, M&A, and investment diligence across global oncology — deepest in ADCs — led by senior deal and clinical judgment, grounded in primary sources.
Senior judgment, in one room.
Accoren is a high-performing biotech deal practice led by Prof. Dr. Kadir Savan, Founder & Chief Medical Officer.
Senior gynecologic-oncology surgeon and clinician-scientist, with decades across academic medicine, surgical practice, and hospital leadership at major oncology-focused institutions. Deep authority in the women’s cancers — ovarian, cervical, and uterine — across the full pathway: diagnosis, pathology, surgical decision-making, treatment sequencing, and follow-up, with clinical command of chemotherapy, radiotherapy, hormone, targeted, and immunotherapy. He brings a physician’s judgment of what actually changes care — the lens drug developers and investors need in one of oncology’s most active arenas for targeted and antibody–drug-conjugate therapy.
The bench
Accoren is a high-performing biotech deal practice. Prof. Dr. Savan leads a senior, multidisciplinary bench — biotech business development and transaction finance, R&D and translational science, regulatory, and commercial specialists — tailored to fit each mandate. Principals run the work; specialist depth is matched to the question.
What we do.
We turn a fast-moving, fragmented evidence base into decisions you can defend.
Asset & company diligence
Scientific credibility, stage, and the real read behind the headline.
Cross-border licensing & deal benchmarking
Economics, rights geography, and how a deal compares.
Partner & buyer mapping
Who is credible, motivated, or misaligned, and why.
Competitive & white-space landscapes
Where a target is crowded and where it isn't.
Catalyst monitoring
The clinical, regulatory, and competitive events that should move a thesis.
BD strategy & investment memos
Source-linked, decision-ready.
Global oncology — deepest in ADCs and the women’s-cancer franchises where ADCs and targeted therapy are most active.
Distinctive specialty: China-to-global oncology partnering.
How we work.
“Not access. Interpretation.”
Evidence over assertion.
Uncertainty disclosed, never hidden.
Senior principals do the work.
Conclusions built to survive diligence.
Our analysis runs on proprietary intelligence infrastructure built by oncology veterans in-house — so the work is faster, fully source-grounded, and repeatable.
What we don’t do
No investment recommendations. No patient-level data. No black-box scores. No insider access.
What you receive.
Every engagement produces structured, source-linked deliverables you can interrogate — not slideware.
Deal Deconstruction
A structured breakdown of one transaction: economics, rights geography, stage, partner logic, and the practical read-through.
Signal Map
What a transaction changes across adjacent assets, categories, and competitive sets.
Partner-Fit Readout
Capability fit, strategic motivation, geography, and what a partner choice signals.
Category Watchlist
Ongoing tracking of deals, assets, and competitive movement in a defined landscape.
Cross-Border Tracker
Early-signal monitoring of China-to-global activity before consensus forms.
✓ Every deliverable’s sources are inspectable.
Recent reads.
Timely, source-grounded reads on the deals shaping oncology — a sample of how we think. The full read-through is a conversation.
Work with us.
Initial consultations are 30 minutes, no obligation.
calendly.com/accoren/deal_chat
Loading the booking calendar. If it doesn’t appear on your network, write to contact@accoren.com and we’ll come back with times.
Or write to contact@accoren.com.